Tofacitinib in the Treatment of IgG4 Related Diseases

Inclusion criteria

• 18 ≤ Age ≤ 70 years old;
• Complies with the 2019 ACR/EULAR IgG4 RD classification criteria
• Patients with initial or recurrent active IgG4 RD (IgG4 RD RI ≥ 3 points).
• Voluntary signing of informed consent: Patients must be given a written consent form when participating in the trial, and it is hoped that patients can comply with the requirements of the study follow-up plan and other protocols;
• Female participants of childbearing age agreed to use effective contraceptive measures during the study period.

Exclusion criteria

• Participants in other trials or those who have participated in clinical trials of other drugs within 2 months;
• Individuals who have received live vaccine immunization within 2 weeks prior to enrollment, or who require live vaccine immunization during the trial period;
• Merge other autoimmune diseases
• Active infected individuals need to be excluded. Latent tuberculosis requires prevention with isoniazid 0.3g/d one month in advance; People with hepatitis B HBsAg+and HBV-DNA negative need to take anti hepatitis B virus drugs one month in advance.
• Pregnant and lactating women, or women of childbearing age who have fertility requirements during the study period and within 6 months after the last dose of medication;
• Patients with a history of thromboembolism, or severe diseases such as coronary heart disease and other important organs such as the heart, brain, liver, lung, kidney, and hematopoietic system, malignant tumors, and psychiatric disorders;
• Other researchers believe that it is not suitable for enrollment.